2 research outputs found
Additional file 2: of Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial
Most common (reported in âĽ2 patients) treatment-emergent adverse events (safety population). (DOCX 18 kb